OPKO Health Research and Development Expenses 2010-2024 | OPK
OPKO Health research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
| OPKO Health Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024 | $105 |
| 2023 | $90 |
| 2022 | $74 |
| 2021 | $77 |
| 2020 | $75 |
| 2019 | $118 |
| 2018 | $126 |
| 2017 | $126 |
| 2016 | $114 |
| 2015 | $99 |
| 2014 | $84 |
| 2013 | $54 |
| 2012 | $20 |
| 2011 | $11 |
| 2010 | $6 |
| 2009 | $11 |
| OPKO Health Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $30 |
| 2024-09-30 | $29 |
| 2024-06-30 | $24 |
| 2024-03-31 | $22 |
| 2023-12-31 | $19 |
| 2023-09-30 | $19 |
| 2023-06-30 | $18 |
| 2023-03-31 | $33 |
| 2022-12-31 | $20 |
| 2022-09-30 | $19 |
| 2022-06-30 | $17 |
| 2022-03-31 | $18 |
| 2021-12-31 | $21 |
| 2021-09-30 | $18 |
| 2021-06-30 | $18 |
| 2021-03-31 | $19 |
| 2020-12-31 | $17 |
| 2020-09-30 | $18 |
| 2020-06-30 | $18 |
| 2020-03-31 | $22 |
| 2019-12-31 | $23 |
| 2019-09-30 | $30 |
| 2019-06-30 | $28 |
| 2019-03-31 | $37 |
| 2018-12-31 | $33 |
| 2018-09-30 | $30 |
| 2018-06-30 | $29 |
| 2018-03-31 | $33 |
| 2017-12-31 | $34 |
| 2017-09-30 | $33 |
| 2017-06-30 | $33 |
| 2017-03-31 | $27 |
| 2016-12-31 | $-70 |
| 2016-09-30 | $24 |
| 2016-06-30 | $31 |
| 2016-03-31 | $128 |
| 2015-12-31 | $25 |
| 2015-09-30 | $19 |
| 2015-06-30 | $30 |
| 2015-03-31 | $26 |
| 2014-12-31 | $26 |
| 2014-09-30 | $21 |
| 2014-06-30 | $16 |
| 2014-03-31 | $21 |
| 2013-12-31 | $23 |
| 2013-09-30 | $11 |
| 2013-06-30 | $10 |
| 2013-03-31 | $10 |
| 2012-12-31 | $7 |
| 2012-09-30 | $4 |
| 2012-06-30 | $4 |
| 2012-03-31 | $5 |
| 2011-12-31 | $4 |
| 2011-09-30 | $3 |
| 2011-06-30 | $3 |
| 2011-03-31 | $1 |
| 2010-12-31 | $2 |
| 2010-09-30 | $2 |
| 2010-06-30 | $2 |
| 2010-03-31 | $1 |
| 2009-12-31 | $0 |
| 2009-09-30 | $3 |
| 2009-06-30 | $2 |
| 2009-03-31 | $6 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.907B | $0.713B |
| OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel. | |||